They are the Chief Executive Officer of bit.bio, leading the company in using opti-ox forward programming technology to deliver scalable, differentiated human cells for drug discovery.
They founded Abcam in 1998, growing it from an idea into a global enterprise with offices in Asia, the UK, and the USA and a market capitalization of over $5bn.
They have invested in and mentored more than 80 startups and are a co-founder of the Milner Therapeutics Institute at the University of Cambridge, and they have served as an ambassador for the Natural History Museum since 2013.
They hold a Doctor of Philosophy in Molecular Genetics from the University of Leicester and completed postdoctoral research at the University of Bath and the University of Cambridge, where they studied the molecular basis of breast cancer in Tony Kouzarides' laboratory.
This person is not in the org chart
This person is not in any teams
This person is not in any offices